Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

16.4K
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
16.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

TRAC in vivo: culmination of CAR and vector engineering.

Cell research·2026
Same author

Tumor irradiation promotes antigen dressing of dendritic cells to enhance CAR T cell persistence and efficacy in lung metastases.

Nature cancer·2026
Same author

Dual CAR-T cell therapy targeting CD19 and BCMA as a novel opportunity for immune reset in systemic lupus erythematosus.

Cellular & molecular immunology·2026
Same author

Development of a Fully Non-Viral 1XX-enhanced BCMA CAR-T Cell Therapy for Multiple Myeloma.

bioRxiv : the preprint server for biology·2026
Same author

A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy.

Cell·2026

相关实验视频

Updated: Feb 16, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.6K

CD19 CAR T 细胞

Michel Sadelain1

  • 1Center for Cell Engineering, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY 10065, USA.

Cell
|December 16, 2017
PubMed
概括

化学抗原受体 (CARs) 重新编程免疫细胞以向瘤. 自主 CAR T 细胞由患者血液生成并扩展以消除癌细胞,提供治疗方法.

科学领域:

  • 免疫学
  • 生物技术
  • 癌症治疗

背景情况:

  • 化学抗原受体 (CAR) 是设计用于治疗应用的免疫细胞重定向的受体.
  • CAR 具有独特的域,对于识别抗原,激活 T 细胞和提供共刺激信号至关重要.

研究的目的:

  • 描述CARs在免疫细胞重编程中的基本结构和功能.
  • 概述产生和利用自主性CAR T细胞用于癌症治疗的过程.

主要方法:

  • 将CARcDNA与T细胞基因组进行基因整合.
  • 从患者外周血液中分离和扩张自身T细胞.
  • 向接受者注射工程化CAR T细胞以消除瘤.

主要成果:

  • 通过CARs成功重新编程免疫细胞.
  • 能够向瘤的功能性自主T细胞的产生.
  • 在接受者体内证明CAR T细胞扩张,以获得持续的治疗效果.

结论:

  • 在采用免疫疗法方面,CAR技术代表了重大进步.
  • 自主 CAR T 细胞治疗提供了个性化的癌症治疗方法.

更多相关视频

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

相关实验视频

Last Updated: Feb 16, 2026

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

15.6K
Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level
08:09

Droplet-based Cytotoxicity Assay to Assess Chimeric Antigen Receptor T cells at the Single-cell Level

Published on: March 14, 2025

1.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K
  • 描述的"从床上到床边"过程突出了CAR T细胞治疗的临床转化.